Head-to-head evidence
Ciltacabtagene autoleucel vs Zevorcabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson and partners
NCT03548207 · Phase 1/2 · completed
This was an open-label, single-group study with no randomized comparator and no blinding. Although the overall response rate among treated participants was high (e.g., 97.1% in the Phase 2 US population with 95% CI 89.8-99.6), the lack of a control arm means the results cannot be attributed to the drug with confidence. Uncontrolled single-arm evidence is inherently limited regardless of the response rate observed.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
Zevorcabtagene autoleucel
Marketed by CARsgen Therapeutics Holdings Limited
NCT03975907 · Phase 1/2 · status unknown
This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · Zevorcabtagene autoleucel's landscape